Naga Chalasani

机构：Indiana University School of Medicine, Indiana University – Purdue University Indianapolis · ORCID：0000-0003-4082-3178

发表论文 832 篇 · 总被引 58963 次 · h-index 108

代表论文

• Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (2025 · New England Journal of Medicine · 被引 114)
• Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study (2025 · The Lancet · 被引 30)
• Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study (2025 · Hepatology · 被引 10)
• Healthy eating and physical activity significantly lower sex-specific alcohol-attributable liver mortality in the United States (2025 · Journal of Hepatology · 被引 8)
• A comprehensive evaluation of candidate genetic polymorphisms in a large histologically characterized MASLD cohort using a novel framework (2025 · Hepatology Communications · 被引 5)
• DRESS Syndrome in Patients With Drug-Induced Liver Injury: Characteristics and HLA Risk Factors (2025 · The American Journal of Gastroenterology · 被引 4)